Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Androgen axis in prostate cancer.

Zoran Culig1, Georg Bartsch

  • 1Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. zoran.culig@uibk.ac.at

Journal of Cellular Biochemistry
|April 7, 2006
PubMed
Summary

Androgen receptor (AR) plays a key role in advanced prostate cancer. Targeting AR expression with novel therapies may inhibit tumor growth and improve patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates.

Cancer treatment reviews·2026
Same author

Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.

Clinical and translational medicine·2026
Same author

Repurposing Amiodarone for Bladder Cancer Treatment.

Cancer research communications·2025
Same author

The MicroRNA miR-454 and the mediator complex component MED12 are regulators of the androgen receptor pathway in prostate cancer.

Scientific reports·2025
Same author

Insights from the Seminal Findings from Puhr et al on the Mechanisms of Docetaxel Resistance in Prostate Cancer.

The American journal of pathology·2025
Same author

Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report.

Therapeutic advances in urology·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Endocrine therapy for advanced prostate cancer relies on androgen ablation or androgen receptor (AR) blockade.
  • AR expression is heterogeneous in prostate cancer, with some cells lacking AR due to epigenetic changes.
  • AR expression can increase with chronic androgen ablation and is upregulated during therapy resistance.

Purpose of the Study:

  • To investigate the role of AR expression and its regulation in advanced prostate cancer.
  • To explore mechanisms of therapy resistance and potential novel therapeutic strategies targeting AR.

Main Methods:

  • Analysis of AR expression in prostate cancer cell lines, xenografts, and patient tumors.
  • Investigation of AR regulation by epigenetic changes, coactivators, and signaling pathways (Ras/MAPK, Her-2/neu, IL-6).
  • Evaluation of therapeutic strategies including chemopreventive drugs and antisense oligonucleotides targeting AR.

Main Results:

  • AR is heterogeneously expressed but generally present in primary tumors and metastases.
  • AR upregulation is a consistent finding in therapy-resistant prostate cancer.
  • AR sensitivity can be modulated by pathways like Ras/MAPK, and coactivator proteins are upregulated in advanced disease.

Conclusions:

  • Overexpression and activation of AR in advanced prostate cancer suggest it as a therapeutic target.
  • Novel therapies aimed at reducing AR expression show promise in inhibiting prostate tumor growth.
  • Understanding AR regulation and resistance mechanisms is crucial for developing effective endocrine therapies.

Related Experiment Videos